GR1004636B - CANCER PROGNOSIS USING THYMOSIN b10 (Tb10) - Google Patents

CANCER PROGNOSIS USING THYMOSIN b10 (Tb10)

Info

Publication number
GR1004636B
GR1004636B GR20010100543A GR2001100543A GR1004636B GR 1004636 B GR1004636 B GR 1004636B GR 20010100543 A GR20010100543 A GR 20010100543A GR 2001100543 A GR2001100543 A GR 2001100543A GR 1004636 B GR1004636 B GR 1004636B
Authority
GR
Greece
Prior art keywords
expression
cancer
evaluation
thymosin
diagnosis
Prior art date
Application number
GR20010100543A
Other languages
Greek (el)
Other versions
GR20010100543A (en
Inventor
Verghese@Νικολακακηασουζαναα
Αποστολικασανικηφοροσα
Ευαγγελατοσαγρηγοριοσα
Ιθακησιοσαδιονυσιοσα
Λεοντιαδησαλεοντιοσα
Λιβανιουαευαγγελιαα
Original Assignee
Εθνικοακεντροαερευνασαφυσικωναεπιστημωνα}Εκεφεbα@Α@Δημοκριτος@Αα
Φαρανααβεεαπαραγωγησακαιαεμποριασαφαρμακωναα
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Εθνικοακεντροαερευνασαφυσικωναεπιστημωνα}Εκεφεbα@Α@Δημοκριτος@Αα, Φαρανααβεεαπαραγωγησακαιαεμποριασαφαρμακωναα filed Critical Εθνικοακεντροαερευνασαφυσικωναεπιστημωνα}Εκεφεbα@Α@Δημοκριτος@Αα
Priority to GR20010100543A priority Critical patent/GR1004636B/en
Priority to AU2002358914A priority patent/AU2002358914A1/en
Priority to PCT/GR2002/000060 priority patent/WO2003046582A2/en
Publication of GR20010100543A publication Critical patent/GR20010100543A/en
Publication of GR1004636B publication Critical patent/GR1004636B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5759—Thymosin or related peptides

Abstract

he invention presents a reliable specific immunohistochemical method, which uses thymosin b10 as a cancer marker with application in the confirmation of diagnosis and prognosis of cancer, and provides guidance for th evaluation of positivity of immunohistochemical expression of thymosin b10 in benign and malignant tissues. The evaluation of the measured Tb10 expression is characterized by the fact thatTb10 expression is correlated with the aggresiveness of the disease, and this correlation is based on the concept that: the weaker the expression of Tb10 in cancer cells, the higher the aggressiveness of the neoplasm and vice versa, that is: the stronger the expression of Tb10 in cancer cells, the lower the aggressiveness of the neoplasm. The invention also describes an in vitro diagnosis kit, which by application of the above-described concept of evaluation of Tb10 expression, provides a means of confirmation of cancer diagnosis and a means of reliable prognosis of its course, and is therefor useful for the better therapeutic handling of cancer. The above method and kit are also applicable in the evaluation of the measurement of other known
GR20010100543A 2001-11-28 2001-11-28 CANCER PROGNOSIS USING THYMOSIN b10 (Tb10) GR1004636B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GR20010100543A GR1004636B (en) 2001-11-28 2001-11-28 CANCER PROGNOSIS USING THYMOSIN b10 (Tb10)
AU2002358914A AU2002358914A1 (en) 2001-11-28 2002-11-28 Cancer prognosis using thymosin beta10 (tbeta10)
PCT/GR2002/000060 WO2003046582A2 (en) 2001-11-28 2002-11-28 CANCER PROGNOSIS USING THYMOSIN β10 (Tβ10)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20010100543A GR1004636B (en) 2001-11-28 2001-11-28 CANCER PROGNOSIS USING THYMOSIN b10 (Tb10)

Publications (2)

Publication Number Publication Date
GR20010100543A GR20010100543A (en) 2003-07-16
GR1004636B true GR1004636B (en) 2004-07-14

Family

ID=10944841

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010100543A GR1004636B (en) 2001-11-28 2001-11-28 CANCER PROGNOSIS USING THYMOSIN b10 (Tb10)

Country Status (3)

Country Link
AU (1) AU2002358914A1 (en)
GR (1) GR1004636B (en)
WO (1) WO2003046582A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103940658A (en) * 2014-04-10 2014-07-23 青岛大学医学院附属医院 Method for manufacturing paraffin-embedded tissue cell specimen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248591A (en) * 1991-05-02 1993-09-28 Puente Fernando D Diagnosis of cancer and other proliferative disorders by analysis of prothymosin alpha expression
US5858681A (en) * 1996-06-17 1999-01-12 Children's Medical Center Method for prognosis of prostate cancer

Also Published As

Publication number Publication date
GR20010100543A (en) 2003-07-16
WO2003046582A2 (en) 2003-06-05
AU2002358914A1 (en) 2003-06-10
WO2003046582A8 (en) 2003-08-07
WO2003046582A3 (en) 2004-02-05
AU2002358914A8 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
HK1030018A1 (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
EP2196474A3 (en) Therapeutic targets in cancer
HUP0202522A2 (en) Radiolabeling kit and binding assay
BR0114716A (en) Tumor biopsy device
AU2004205878A8 (en) Gene expression markers for breast cancer prognosis
IL155611A0 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
MXPA04006517A (en) Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours.
DE50207866D1 (en) USE OF SOLUBLE CYTOKERATIN-1-FRAGMENTS IN DIAGNOSTIC
DE60032784D1 (en) MARKER PROTEINS FOR PROSTATE CANCER
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
WO2007107774A3 (en) Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer
DK1173766T3 (en) Isoform of tenascin-C as a marker for neoplasia
GR20010100543A (en) CANCER PROGNOSIS USING THYMOSIN b10 (Tb10)
MX2007005501A (en) Tumor association of mdl-1 and methods.
EP2267450A3 (en) Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
AU2001294165A1 (en) Apparatus for prostate cancer diagnose
WO2002023200A3 (en) Human breast cancer biomarkers
WO2003024302A3 (en) Detection and treatment of cancers of breast
AU2002306568A1 (en) Forms of prostate specific antigens and methods for their detection
TW200632319A (en) Ex vivo cancer diagnostic method
WO2002055555A3 (en) Antigenic ck-18 compounds for therapy and diagnosis and methods for using same
WO2003058198A3 (en) Human breast cancer biomarkers
AU2002326318A1 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer
WO2006021874A8 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer